Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Neut-X can be successfully used as diagnostic and prognostic tool in MDS.

Boquoi A, Barthuber C, Strapatsas J, Kuendgen A, Kobbe G, Fenk R, Gattermann N, Haas R, Germing U.

Leuk Res. 2019 Nov;86:106224. doi: 10.1016/j.leukres.2019.106224. Epub 2019 Sep 13. No abstract available.

PMID:
31586853
2.

Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients.

Silzle T, Blum S, Schuler E, Kaivers J, Rudelius M, Hildebrandt B, Gattermann N, Haas R, Germing U.

Blood Cancer J. 2019 Aug 9;9(8):63. doi: 10.1038/s41408-019-0223-7.

3.

Novel therapies in low- and high-risk myelodysplastic syndrome.

Germing U, Schroeder T, Kaivers J, Kündgen A, Kobbe G, Gattermann N.

Expert Rev Hematol. 2019 Oct;12(10):893-908. doi: 10.1080/17474086.2019.1647778. Epub 2019 Jul 31.

PMID:
31353975
4.

Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromes.

Kobbe G, Schroeder T, Rautenberg C, Kaivers J, Gattermann N, Haas R, Germing U.

Expert Rev Hematol. 2019 Oct;12(10):821-831. doi: 10.1080/17474086.2019.1645004. Epub 2019 Jul 25.

PMID:
31322458
5.

Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.

Leitch HA, Gattermann N.

Crit Rev Oncol Hematol. 2019 Sep;141:54-72. doi: 10.1016/j.critrevonc.2019.06.002. Epub 2019 Jun 10. Review.

PMID:
31228649
6.

Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial.

Garcia-Manero G, Almeida A, Fenaux P, Gattermann N, Giagounidis A, Goldberg SL, Ozawa K, Weaver J, Santini V.

Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):213-219.e4. doi: 10.1016/j.clml.2018.12.012. Epub 2018 Dec 21.

PMID:
30770308
7.

Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.

Schuler E, Zadrozny N, Blum S, Schroeder T, Strupp C, Hildebrandt B, Kündgen A, Gattermann N, Aul C, Kondakci M, Kobbe G, Haas R, Germing U.

Ann Hematol. 2018 Dec;97(12):2325-2332. doi: 10.1007/s00277-018-3466-7. Epub 2018 Aug 4.

PMID:
30078145
8.

The IPSS-R has prognostic impact in untreated patients with MDS del(5q).

Kaivers J, Lauseker M, Hildebrandt B, Fenaux P, Pfeilstöcker M, Valent P, Platzbecker U, Latagliata R, Oliva EN, Xicoy B, Götze K, Ganster C, Haase D, Bug G, Kündgen A, Gattermann N, Haas R, Germing U.

Leuk Res. 2018 Sep;72:27-33. doi: 10.1016/j.leukres.2018.07.019. Epub 2018 Jul 23.

PMID:
30075323
9.

Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.

Kuendgen A, Müller-Thomas C, Lauseker M, Haferlach T, Urbaniak P, Schroeder T, Brings C, Wulfert M, Meggendorfer M, Hildebrandt B, Betz B, Royer-Pokora B, Gattermann N, Haas R, Germing U, Götze KS.

Oncotarget. 2018 Jun 12;9(45):27882-27894. doi: 10.18632/oncotarget.25328. eCollection 2018 Jun 12. Review.

10.

Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int-1-risk MDS patients: Results of the phase II KALLISTO trial.

Gattermann N, Coll R, Jacobasch L, Allameddine A, Azmon A, DeBonnett L, Bruederle A, Jin J; KALLISTO study investigators.

Eur J Haematol. 2018 May 19. doi: 10.1111/ejh.13096. [Epub ahead of print]

PMID:
29777631
11.

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.

Ross DM, Masszi T, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, Garcia-Gutierrez V, Gattermann N, le Coutre PD, Martino B, Saussele S, Giles FJ, Radich JP, Saglio G, Deng W, Krunic N, Bédoucha V, Gopalakrishna P, Hochhaus A.

J Cancer Res Clin Oncol. 2018 May;144(5):945-954. doi: 10.1007/s00432-018-2604-x. Epub 2018 Feb 22.

12.

Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.

Schuler E, Frank F, Hildebrandt B, Betz B, Strupp C, Rudelius M, Aul C, Schroeder T, Gattermann N, Haas R, Germing U.

Leuk Res. 2018 Feb;65:1-4. doi: 10.1016/j.leukres.2017.12.002. Epub 2017 Dec 5.

PMID:
29216536
13.

Iron overload in myelodysplastic syndromes (MDS).

Gattermann N.

Int J Hematol. 2018 Jan;107(1):55-63. doi: 10.1007/s12185-017-2367-1. Epub 2017 Nov 25. Review.

PMID:
29177643
14.

Myelodysplastic syndromes (MDS) in regular care in Germany - the oldest patients come to the fore.

Steinmetz HT, Germing U, Sauer A, Lathan B, Liersch R, Tesch H, Heßling J, Moorahrend E, Uhlig J, Reiser M, Wahdat R, Gattermann N, Totzke U, Schmitz S.

Leuk Lymphoma. 2018 May;59(5):1244-1247. doi: 10.1080/10428194.2017.1375105. Epub 2017 Sep 15. No abstract available.

PMID:
28914552
15.

Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis.

Neukirchen J, Lauseker M, Hildebrandt B, Nolting AC, Kaivers J, Kobbe G, Gattermann N, Haas R, Germing U.

Cancer. 2017 Dec 1;123(23):4608-4616. doi: 10.1002/cncr.30917. Epub 2017 Jul 26.

16.

A retrospective study evaluating the impact of infectious complications during azacitidine treatment.

Schuck A, Goette MC, Neukirchen J, Kuendgen A, Gattermann N, Schroeder T, Kobbe G, Germing U, Haas R.

Ann Hematol. 2017 Jul;96(7):1097-1104. doi: 10.1007/s00277-017-3001-2. Epub 2017 May 4.

PMID:
28474144
17.

New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types.

Strupp C, Nachtkamp K, Hildebrandt B, Giagounidis A, Haas R, Gattermann N, Bennett JM, Aul C, Germing U.

Leuk Res. 2017 Jun;57:78-84. doi: 10.1016/j.leukres.2017.02.008. Epub 2017 Feb 27.

PMID:
28324772
18.

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.

Hochhaus A, Mahon FX, le Coutre P, Petrov L, Janssen JJWM, Cross NCP, Rea D, Castagnetti F, Hellmann A, Rosti G, Gattermann N, Coronel MLP, Gutierrez MAE, Garcia-Gutierrez V, Vincenzi B, Dezzani L, Giles FJ.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1225-1233. doi: 10.1007/s00432-017-2359-9. Epub 2017 Feb 21.

19.

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, García-Gutiérrez V, Gattermann N, Wiktor-Jedrzejczak W, le Coutre PD, Martino B, Saussele S, Menssen HD, Deng W, Krunic N, Bedoucha V, Saglio G.

Leukemia. 2017 Jul;31(7):1525-1531. doi: 10.1038/leu.2017.63. Epub 2017 Feb 20.

20.

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

Schlenk RF, Stegelmann F, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau IW, Verbeek W, Heidel FH, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Grießhammer M, Döhner K.

Leukemia. 2017 Apr;31(4):889-895. doi: 10.1038/leu.2016.299. Epub 2016 Oct 24.

PMID:
27774990
21.

Iron rusting in the mitochondria?

Gattermann N.

Blood. 2016 Oct 13;128(15):1907-1908. No abstract available.

PMID:
27737844
22.

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.

Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Ram R, Del Cañizo C, Gattermann N, Ozawa K, Risueño A, MacBeth KJ, Zhong J, Séguy F, Hoenekopp A, Beach CL, Fenaux P.

J Clin Oncol. 2016 Sep 1;34(25):2988-96. doi: 10.1200/JCO.2015.66.0118. Epub 2016 Jun 27.

PMID:
27354480
23.

Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.

Kaifie A, Isfort S, Gattermann N, Hollburg W, Klausmann M, Wolf D, Maintz C, Hänel M, Goekkurt E, Göthert JR, Platzbecker U, Geer T, Parmentier S, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL).

Ann Hematol. 2016 Sep;95(9):1399-410. doi: 10.1007/s00277-016-2730-y. Epub 2016 Jun 22.

PMID:
27334946
24.

γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm.

Görtzen J, Hunka LM, Vonnahme M, Praktiknjo M, Kaifie A, Fimmers R, Jansen C, Heine A, Lehmann J, Goethert JR, Gattermann N, Goekkurt E, Platzbecker U, Brossart P, Strassburg CP, Brummendorf TH, Koschmieder S, Wolf D, Trebicka J.

Medicine (Baltimore). 2016 May;95(20):e3355. doi: 10.1097/MD.0000000000003355.

25.

Causes of death in 2877 patients with myelodysplastic syndromes.

Nachtkamp K, Stark R, Strupp C, Kündgen A, Giagounidis A, Aul C, Hildebrandt B, Haas R, Gattermann N, Germing U.

Ann Hematol. 2016 May;95(6):937-44. doi: 10.1007/s00277-016-2649-3. Epub 2016 Mar 30.

PMID:
27025507
26.

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.

Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, Gökkurt E, Platzbecker U, Hollburg W, Göthert JR, Parmentier S, Lang F, Hansen R, Isfort S, Schmitt K, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL).

J Hematol Oncol. 2016 Mar 5;9:18. doi: 10.1186/s13045-016-0242-9.

27.

New insights into transfusion-related iron toxicity: Implications for the oncologist.

Porter JB, de Witte T, Cappellini MD, Gattermann N.

Crit Rev Oncol Hematol. 2016 Mar;99:261-71. doi: 10.1016/j.critrevonc.2015.11.017. Epub 2015 Nov 27. Review.

PMID:
26806144
28.

Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).

Schuler E, Giagounidis A, Haase D, Shirneshan K, Büsche G, Platzbecker U, Nolte F, Götze K, Schlenk RF, Ganser A, Letsch A, Braulke F, Lübbert M, Bug G, Schafhausen P, Bacher U, Gattermann N, Wulfert M, Haas R, Germing U.

Leukemia. 2016 Jul;30(7):1580-2. doi: 10.1038/leu.2015.340. Epub 2015 Dec 15. No abstract available.

PMID:
26668126
29.

Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide.

Beier F, Masouleh BK, Buesche G, Ventura Ferreira MS, Schneider RK, Ziegler P, Wilop S, Vankann L, Gattermann N, Platzbecker U, Giagounidis A, Götze KS, Nolte F, Hofmann WK, Haase D, Kreipe H, Panse J, Blasco MA, Germing U, Brümmendorf TH.

Leuk Res. 2015 Sep 21. pii: S0145-2126(15)30380-5. doi: 10.1016/j.leukres.2015.09.003. [Epub ahead of print]

PMID:
26427727
30.

Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulations.

Nolte F, Angelucci E, Breccia M, Gattermann N, Santini V, Vey N, Hofmann WK.

Leuk Res. 2015 Oct;39(10):1028-33. doi: 10.1016/j.leukres.2015.06.008. Epub 2015 Jun 20. Review.

PMID:
26293555
31.

In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.

Lauseker M, Schemenau J, Strupp C, Kündgen A, Gattermann N, Hasford J, Germing U.

Br J Haematol. 2015 Sep;170(5):687-93. doi: 10.1111/bjh.13496. Epub 2015 May 11.

PMID:
25960152
32.

Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes.

Hejazi M, Manser AR, Fröbel J, Kündgen A, Zhao X, Schönberg K, Germing U, Haas R, Gattermann N, Uhrberg M.

Haematologica. 2015 May;100(5):643-52. doi: 10.3324/haematol.2014.118679. Epub 2015 Feb 14.

33.

Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes.

Schemenau J, Baldus S, Anlauf M, Reinecke P, Braunstein S, Blum S, Nachtkamp K, Neukirchen J, Strup C, Aul C, Haas R, Gattermann N, Germing U.

Eur J Haematol. 2015 Sep;95(3):181-9. doi: 10.1111/ejh.12512. Epub 2015 May 15. Review.

PMID:
25600827
34.

Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias.

Schuler E, Schroeder M, Neukirchen J, Strupp C, Xicoy B, Kündgen A, Hildebrandt B, Haas R, Gattermann N, Germing U.

Leuk Res. 2014 Dec;38(12):1413-9. doi: 10.1016/j.leukres.2014.09.003. Epub 2014 Sep 17.

PMID:
25444076
35.

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.

Santini V, Prebet T, Fenaux P, Gattermann N, Nilsson L, Pfeilstöcker M, Vyas P, List AF.

Leuk Res. 2014 Dec;38(12):1381-91. doi: 10.1016/j.leukres.2014.09.008. Epub 2014 Sep 22. Review.

36.

Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia.

Sonnet M, Claus R, Becker N, Zucknick M, Petersen J, Lipka DB, Oakes CC, Andrulis M, Lier A, Milsom MD, Witte T, Gu L, Kim-Wanner SZ, Schirmacher P, Wulfert M, Gattermann N, Lübbert M, Rosenbauer F, Rehli M, Bullinger L, Weichenhan D, Plass C.

Genome Med. 2014 Apr 30;6(4):34. doi: 10.1186/gm551. eCollection 2014.

37.

When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?

Steensma DP, Gattermann N.

Best Pract Res Clin Haematol. 2013 Dec;26(4):431-44. doi: 10.1016/j.beha.2013.09.009. Epub 2013 Oct 1. Review. Erratum in: Best Pract Res Clin Haematol. 2014 Jun;27(2):e1.

PMID:
24507819
38.

The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system.

Zipperer E, Tanha N, Strupp C, Kündgen A, Nachtkamp K, Neukirchen J, Hildebrandt B, Haas R, Gattermann N, Germing U.

Haematologica. 2014 Mar;99(3):e31-2. doi: 10.3324/haematol.2013.101055. Epub 2014 Jan 24. No abstract available.

39.

Myelodysplastic syndromes: diagnosis, prognosis, and treatment.

Germing U, Kobbe G, Haas R, Gattermann N.

Dtsch Arztebl Int. 2013 Nov 15;110(46):783-90. doi: 10.3238/arztebl.2013.0783. Review.

40.

Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients.

Platzbecker U, Al-Ali HK, Gattermann N, Haase D, Janzen V, Krauter J, Götze K, Schlenk R, Nolte F, Letsch A, Ottmann OG, Kündgen A, Lübbert M, Germing U, Wermke M, Reinhard H, Weiss C, Lieder K, Ehninger G, Leismann O, Giagounidis A.

Leukemia. 2014 Mar;28(3):696-8. doi: 10.1038/leu.2013.325. Epub 2013 Nov 4. No abstract available.

PMID:
24186004
41.

The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany.

Gattermann N, Kündgen A, Kellermann L, Zeffel M, Paessens B, Germing U.

Eur J Haematol. 2013 Dec;91(6):473-82. doi: 10.1111/ejh.12196. Epub 2013 Sep 18.

PMID:
24102637
42.

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, Del Cañizo C, Della Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M; European Leukemia Net.

Blood. 2013 Oct 24;122(17):2943-64. doi: 10.1182/blood-2013-03-492884. Epub 2013 Aug 26.

43.

Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome.

Zipperer E, Post JG, Herkert M, Kündgen A, Fox F, Haas R, Gattermann N, Germing U.

Ann Hematol. 2013 Dec;92(12):1617-23. doi: 10.1007/s00277-013-1839-5. Epub 2013 Jul 11.

PMID:
23842708
44.

Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells.

Geyh S, Oz S, Cadeddu RP, Fröbel J, Brückner B, Kündgen A, Fenk R, Bruns I, Zilkens C, Hermsen D, Gattermann N, Kobbe G, Germing U, Lyko F, Haas R, Schroeder T.

Leukemia. 2013 Sep;27(9):1841-51. doi: 10.1038/leu.2013.193. Epub 2013 Mar 29.

PMID:
23797473
45.

Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.

Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM.

Leukemia. 2013 Apr;27(4):907-13. doi: 10.1038/leu.2012.305. Epub 2012 Nov 6.

46.

Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts.

Maassen A, Strupp C, Giagounidis A, Kuendgen A, Nachtkamp K, Hildebrandt B, Gattermann N, Aul C, Haas R, Germing U.

Leuk Res. 2013 Jan;37(1):64-70. doi: 10.1016/j.leukres.2012.09.021. Epub 2012 Oct 31.

PMID:
23122806
47.

SF3B1 and the riddle of the ring sideroblast.

Gattermann N.

Blood. 2012 Oct 18;120(16):3167-8. doi: 10.1182/blood-2012-08-447094. No abstract available.

PMID:
23086622
48.

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.

Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.

PMID:
23073603
49.

Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias.

Viprakasit V, Gattermann N, Lee JW, Porter JB, Taher AT, Habr D, Martin N, Domokos G, Cappellini MD.

Blood Transfus. 2013 Jan;11(1):108-22. doi: 10.2450/2012.0012-12. Epub 2012 Jul 12.

50.

Supplemental Content

Loading ...
Support Center